ReviewNature reviews. Disease primers2024
Leprosy.
Review in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Management and outcomes of acute hand and wrist infections in low- and middle-income countries : a systematic review and meta-analysis.Bone & joint open · 2026Pooled it
- A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy.PLoS neglected tropical diseases · 2026Pooled it
- Methotrexate and Prednisolone compared to placebo and prednisolone in the treatment of severe Erythema Nodosum Leprosum: An international multicentre, double-blind randomised controlled clinical trial-MaPs in ENL.PLoS neglected tropical diseases · 2026Trial
- Longitudinal performance of the ENLIST ENL severity scale in individuals with severe erythema nodosum leprosum: Responsiveness, trajectories and clinical features - a secondary analysis of the Methotrexate and Prednisolone study - MaPs in ENL.PLoS neglected tropical diseases · 2026Trial
- Integrated skin-lesion transcriptomics prioritises biomarker-candidate host-response genes with pharmacological annotation in leprosy type 1 reaction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Multibacillary leprosy - a diagnostic and therapeutic challenge.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Diagnostic Challenges of Lepromatous Leprosy in a Non-Endemic Setting: A Case of Atypical Primary Hyperpigmentation.International journal of dermatology · 2026Article
- miR-889-3p targets SLC35E1 in leprosy: Implications for therapeutic monitoring.PLoS neglected tropical diseases · 2026Article
- Glycosylation profile ofiScience · 2026Article
- Impact of rigid contact lens use on visual acuity and vision-related quality of life in keratoconus.International ophthalmology · 2026Observational
- Identification of Mycobacterium leprae and Mycobacterium lepromatosis Cases with Broad-Range Molecular Assays at a Single Large Reference Laboratory.The American journal of tropical medicine and hygiene · 2026Article
- Seroprevalence ofThe Lancet regional health. Southeast Asia · 2026Article
- A rare case of benign isolated follicular mucinosis with significant eosinophilic infiltration.JAAD case reports · 2026Article
- Lewis Y (LeImmunologic research · 2026Article
- Tropical infectious diseases and skin manifestations: a diagnostic framework.Current opinion in infectious diseases · 2026Review
- A Rare Case of Leprosy in Sweden Mimicking Drug Eruption.Acta dermato-venereologica · 2026Article
- Serum geoepidemiology of leprosy biomarkers in a city-wide COVID-19 survey in Brazil.BMC infectious diseases · 2026Article
- Independent assessment of the WHO Skin Neglected Tropical Diseases application for leprosy detection.Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Economic cost of Hansen's disease: an overview of social security expenditures.Frontiers in public health · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy, a neglected tropical disease, causes significant morbidity in marginalized communities. Before the COVID-19 pandemic, annual new case detection plateaued for over a decade at ~200,000 new cases. The clinical phenotypes of leprosy strongly parallel host immunity to its causative agents Mycobacterium leprae and Mycobacterium lepromatosis. The resulting spectrum spans from paucibacillary leprosy, characterized by vigorous pro-inflammatory immunity with few bacteria, to multibacillary leprosy, harbouring large numbers of bacteria with high levels of seemingly non-protective, anti-M. leprae antibodies. Leprosy diagnosis remains clinical, leaving asymptomatic individuals with infection undetected. Antimicrobial treatment is effective with recommended multidrug therapy for 6 months for paucibacillary leprosy and 12 months for multibacillary leprosy. The incubation period ranges from 2 to 6 years, although longer periods have been described. Given this lengthy incubation period and dwindling clinical expertise, there is an urgent need to create innovative, low-complexity diagnostic tools for detection of M. leprae infection. Such advancements are vital for enabling swift therapeutic and preventive interventions, ultimately transforming patient outcomes. National health-care programmes should prioritize early case detection and consider post-exposure prophylaxis for individuals in close contact with affected persons. These measures will help interrupt transmission, prevent disease progression, and mitigate the risk of nerve damage and disabilities to achieve the WHO goal 'Towards Zero Leprosy' and reduce the burden of leprosy.
Indexed as
Identifiers
39609422What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.